Announcements - OBI Pharma 台灣浩鼎

2018.Sep.28

Taiwan FDA clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study

2018.Sep.20

Correction on previous announcement: “Clarification on the news article by Commercial Times” to “United Daily News”

2018.Sep.20

Clarification on the news article by Commercial Times

2018.Sep.19

OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL)

2018.Sep.03

OBI Pharma Inc. to attend 2018 industry forum hosted by Masterlink Securities

2018.Aug.15

OBI received notice from patent attorney’s office that product patent for OBI-3424 named "DNA alkylating agents" has been approved by IP Australia

2018.Jul.30

Clarification on the news article by Commercial Times

2018.Jul.27

Investigational Device Exemption (IDE) for the development of Adagloxad Simolenin (OBI-822) was approved by the US Food and Drug Administration (FDA) for its use in OBI-822 Phase III Clinical Trial

2018.Jul.08

OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Hepatocellular Carcinoma (HCC)

2018.Jun.27

Announcement on the board resolution at Annual General Meeting 2018

News

Latest News

Events

Latest events